PPH - Healthcare dealmakers see increased M&A valuations in 2024: KPMG
2024-02-19 15:48:49 ET
More on iShares Biotechnology ETF, iShares U.S. Medical Devices ETF, etc.
- XLV: Low-Cost Exposure To A Defensive Sector, While Achieving Strong Performance
- THQ Vs. XBI: Keeping The Biotech ETF For Now
- XBI: Biotech Speculation
- Top 10 ETFs have the lowest weighted average free cash flow yield - GS
- Communication Services, Info Tech and Healthcare jump into overbought territory